Total-FGFR1 cellular kit HTRF®
The Total-FGFR1 kit monitors the cellular FGFR1 expression level, and can be used as a normalization assay for the Phospho-FGFR1 kit.
- Highly specific
The Total-FGFR1 cellular assay monitors total FGFR1, and can be used as a normalization assay with the Phospho-FGFR1 kit. Mutations in FGFR1 have been associated with a wide variety of cancers, including lung, breast, urothelial, or ovarian cancers.
- DATA NORMALIZATION
The HTRF Total-FGFR1 assay quantifies the expression level of FGFR1 in a cell lysate. Unlike Western Blot, the assay is entirely plate-based and does not require gels, electrophoresis, or transfer. The Total-FGFR1 assay uses two labeled antibodies: one coupled to a donor fluorophore, the other to an acceptor. Both antibodies are highly specific for a distinct epitope on the protein. In presence of FGFR1 in a cell extract, the addition of these conjugates brings the donor fluorophore into close proximity with the acceptor, and thereby generates a FRET signal. Its intensity is directly proportional to the concentration of the protein present in the sample, and provides a means of assessing the protein’s expression under a no-wash assay format.
The 2 plate protocol involves culturing cells in a 96-well plate before lysis, then transferring lysates to a 384-well low volume detection plate before the addition of the Total-FGFR1 HTRF detection reagents. This protocol enables the cells' viability and confluence to be monitored.
Detection of total FGFR1 with HTRF reagents can be performed in a single plate used for culturing, stimulation, and lysis. No washing steps are required. This HTS-designed protocol enables miniaturization while maintaining robust HTRF quality.
Different human cancer cell lines were seeded in T175 flasks in complete culture medium at 37°C, 5% CO2. The cells were then lysed with 3 mL of supplemented lysis buffer #4 (1X) for 30 minutes at RT under gentle shaking.
25 µg of total protein for each cell line and 15 µg for the KG-1 cell line were analyzed for their total FGFR1-2 -3 and -4 protein levels. 16 µL of normalized samples were transferred into a 384 well low volume white microplate and 4 µL of HTRF Total-FGFR1, FGFR2, FGFR3, or FGFR4 detection antibodies were added. The HTRF signal was recorded after an overnight incubation. The results show different expression patterns for the four different FGFR receptors. Whereas FGFR1 is expressed at high levels in the DMS114 cell lung cancer model and the KG-1 bone marrow myelogenous leukaemia model, FGFR2 is preferentially expressed in SNU-16 and the Kato-III gastric cancer model, FGFR3 in the KMS-11 multiple myeloma cell line, and FGFR4 in the MDA-MD-453 breast cancer model or HuH7 hepatocarcinoma cell line. Moreover, these results demonstrate the recognition specificity provided by the HTRF Total-FGFR kits.
Human KG-1 cells (bone marrow myelogenous leukaemia) were seeded in a half area 96-well culture-treated plate at 200,000 cells/well in 25 µL complete culture medium. Cells were treated with 5 µL of increasing concentrations of AZD4547, an FGFR Inhibitor, for 24h at 37 °C, 5% CO2. After treatment, cells were lysed with 10µl of supplemented lysis buffer #4 (4X) for 30 min at RT under gentle shaking.
Human DMS-114 cells (lung carcinoma) were plated in a 96-well plate (100,000 cells/well) and incubated overnight. Cells were next treated with a dose-response of AZD4547 for 24h at 37 °C, 5% CO2, then stimulated for 10 min with 100 ng/ml FGF2. After treatment, cells were lysed with 25µl of supplemented lysis buffer #4 (1X) for 30 min at RT under gentle shaking.
After cell lysis, 16 µL of lysate were transferred into a 384-well sv white microplate and 4 µL of the HTRF Phospho-FGFR1 (Tyr653/654) or Total-FGFR1 detection reagents were added. The HTRF signal was recorded after an overnight incubation at room temperature.
As expected, the results obtained show a dose-response inhibition of FGFR1 Y653/654 phosphorylation upon treatment with AZD4547, while the FGFR1 expression level remains constant.
KG-1 cells were cultured in a T175 flask in complete culture medium at 37°C, 5% CO2. After 72h incubation, the cells were lysed with 3 mL of supplemented lysis buffer #4 (1X) for 30 minutes at RT under gentle shaking.
Serial dilutions of the cell lysate were performed using supplemented lysis buffer, and 16 µL of each dilution were transferred into a low volume white microplate before the addition of 4 µL of HTRF Total-FGFR1 detection reagents. Equal amounts of lysates were used for a side by side comparison between HTRF and Western Blot.
The side by side comparison of Western Blot and HTRF demonstrates that the HTRF assay is 4-fold more sensitive than the Western Blot, at least under these experimental conditions.
FGFRs are tyrosine kinase receptors activated by the binding of FGF ligands. This binding drives receptor homodimerization, leading to the activation of the FGFR tyrosine kinase domain and specific tyrosine residue phosphorylation. The activated receptor is a docking site for a variety of proteins that induce downstream activation of several signal transduction cascades, including the RAS-MAPK, PI3K-AKT, PLCγ, and STAT pathways.
FRS2α is a key adaptor protein constitutively associated with FGFRs. Activated FGFR phosphorylates FRS2, allowing the recruitment of GRB2 and SOS to activate RAS and the downstream RAF and MAPK pathways, particularly ERK1/2. Via GAB1, GRB2 also activates PI3K, which then phosphorylates AKT. Independently of FRS2, the binding of PLCg to the intracellular part of the activated FGFRs leads to the production of IP3 and DAG by the hydrolysis of PIP2. DAG activates the enzyme PKC, which partly reinforces the activation of the MAPK pathway. Depending on the cellular context other pathways are also activated by FGFRs, such as STAT signaling.
The signals transmitted from the FGFRs to the nucleus lead to the regulation of various biological functions such as cell proliferation, differentiation, survival, adhesion, migration, and angiogenesis. Alterations to FGFRs in a wide variety of cancers are associated with the overexpression or hyperactivity of FGFRs, making the receptors key targets for anti-cancer therapies.
Physiologically relevant results fo fast flowing research - Flyers
Insider Tips for successful sample treatment - Technical Notes
HTRF and WB compatible guidelines - Technical Notes
Protocol for tumor xenograft analysis with HTRF - Technical Notes
Mastering the art of cell signaling assays optimization - Guides
Multi-tissue cellular modeling and anlysis of insulin signaling - Posters
A solution for phospho-protein analysis in metabolic disorders - Posters
Detailed protocol and direct comparison with WB - Posters
A single technology for 2D cells, 3D cells, and xenograft models - Posters
PI3K/AKT/mTor translational control pathway - Posters
Analysis of a large panel of diverse biological samples and cellular models - Posters
One technology across all samples - Application Notes
Tumor xenograft analysis: HTRF versus Western blot - Application Notes
Valuable guidelines for efficiently analyzing and interpreting results - Application Notes
Increased flexibility of phospho-assays - Application Notes
Analyse of PI3K/AKT/mTor translational control pathway - Application Notes
In collaboration with Bayer - Scientific Presentations
A fun video introducing you to phosphorylation assays with HTRF - Videos
Plate Reader Requirement
Choosing the right microplate reader ensures you’ll get an optimal readout. Discover our high performance reader, or verify if your lab equipment is going to be compatible with this detection technology.Let's find your reader